



COVID-19 Immunization for Individuals with Allergies and Other Health Conditions

August 2022

Allergy (Skin) Testing

- Allergy (Skin) testing is not recommended prior to COVID-19 vaccine administration.
- COVID-19 vaccine is not approved for this indication and will not be provided to clinicians for this purpose.
- The validity of epicutaneous and intradermal testing for COVID-19 vaccines has not been established.¹
- Based on expert opinion, skin testing with the vaccine has not been helpful in determining if patients will react to COVID-19 immunization.²

This policy is evergreen and will be updated as new information becomes available.

Issue	Recommendation			
Previous Anaphylaxis to:				
Note: All events of anaphylaxis should be reported to Alberta Health Services (AHS) as per the instructions available here . AHS Medical Officer of Health/designate will conduct an assessment and follow AHS processes for referral to an allergist. Consultation with an allergist or another physician with expertise in allergy assessment is recommended following anaphylaxis to any vaccine.				
mRNA COVID-19	To proceed with an mRNA vaccine			
vaccine (Pfizer or Moderna)	Consultation with an allergist or another physician with expertise in allergy assessment is recommended prior to receiving a subsequent dose of mRNA vaccine. ³			
	Recommendations for future doses will be based on the advice of the allergist and AHS Medical Officer of Health/designate.			
	Alternatively complete subsequent dose(s) with Novavax.			
	Consultation with allergist or another physician with expertise in allergy assessment is <u>not</u> required prior to receiving Novavax_vaccine.			
	Recommend 30 minute wait after immunization.			
AstraZeneca/ COVISHIELD COVID-19 vaccine	Recommend mRNA vaccine for subsequent doses. Consultation with an allergist or another physician with expertise in allergy assessment is <u>not</u> required before receiving the mRNA vaccine.			
	If mRNA vaccine is contraindicated, recommend Novavax for subsequent dose(s). Consultation with an allergist or another physician with expertise in allergy assessment is not required before receiving the Novavax vaccine.			
	Recommend 30 minute wait after immunization.			
Janssen COVID-19	Recommend mRNA or Novavax for subsequent dose(s).			
vaccine	Consultation with an allergist or another physician with expertise in allergy assessment is not required before receiving the mRNA or Novavax vaccine.			
	Recommend 30 minute wait after immunization.			
Novavax COVID-19 vaccine	Recommend mRNA vaccine for subsequent dose(s). Consultation with an allergist or another physician with expertise in allergy assessment is <u>not</u> required before receiving the mRNA vaccine.			
	Recommend 30 minute wait after immunization			
	If mRNA vaccine is contraindicated, consultation with an allergist or another physician with expertise in allergy assessment is recommended prior to receiving a subsequent dose of vaccine.			





Issue	Recommendation		
Component of the vaccine (eg. PEG)	Confirm history of documented anaphylaxis to the component including reviewing history of tolerance to common medications (see table 2).		
	If anaphylaxis confirmed, provide alternative COVID-19 vaccine. • PEG allergy – offer Novavax (if 18 years of age or older). • Tromethamine allergy – offer Purple Cap Pfizer (dilution required) formulation (if 12 years of age or older) or Novavax (if 18 years of age or older) • Polysorbate allergy – offer mRNA vaccine		
	If able to tolerate medications in table 2, proceed with COVID-19 immunization. NO allergy assessment is required.		
	Recommend 30 minute wait after immunization.		
	If anaphylaxis confirmed to both PEG and Polysorbate, consultation with an allergist or another physician with expertise in allergy assessment is recommended prior to receiving a subsequent dose of vaccine.		
To any other vaccines	Proceed with COVID-19 immunization		
	There is no contraindication to receipt of COVID-19 vaccine for those with a history of anaphylaxis to other vaccines.		
	Recommend 30 minute wait after immunization.		
Previous allergic reactions (non-anaphylaxis) to:			
mRNA vaccine (Pfizer or	Proceed with COVID-19 immunization		
Moderna)	NO allergy assessment is required		
AstraZeneca/	Proceed with COVID-19 immunization		
COVISHIELD vaccine	NO allergy assessment is required		
Janssen vaccine	Proceed with COVID-19 immunization NO allergy assessment is required		
Novavax vaccine	Proceed with COVID-19 immunization		
Tiovavax vaccine	NO allergy assessment is required		
To component of COVID-	Proceed with COVID-19 immunization		
19 Vaccine	NO allergy assessment is required		
To any other vaccines	Proceed with COVID-19 immunization		
,	NO allergy assessment is required		
Other health conditions/issues			
Autoimmune conditions	Proceed with COVID-19 immunization		
	NO allergy assessment is required		
Immunodeficiencies	Proceed with COVID-19 immunization		
	NO allergy assessment is required		
Mast Cell disorders	Proceed with COVID-19 immunization		
	NO allergy assessment is required		
Other non-vaccine	Proceed with COVID-19 immunization		
related allergies	NO allergy assessment is required		

Table 2

Other products containing	Other products containing	Other products containing
PEG	Tromethamine (Tris)	Polysorbate 80
 Cough syrup Laxatives Medical bowel preparation products for colonoscopy Skin care products Dermal fillers Cosmetics Contact lens solutions Ultrasound gel 	Component in contrast media, oral and parenteral medications.	Medical preparations Vitamin oils Tablets Anticancer agents Cosmetics





References:

- 1 Canadian Society of Allergy and Clinical Immunology (April 10, 2021). https://csaci.ca/wp-content/uploads/2021/04/2021-04-10-UPDATE-COVID-19-Vaccine-Testing-Administration-Guidance.pdf
- 2 Alberta Experts physicians specializing in allergies.
- 3 National Advisory Committee on Immunization. (2021). Recommendations on the use of COVID-19 vaccines. https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf

